CN Patent

CN1633281A — 口内崩解的伐地考昔组合物

Assigned to PharMetrix Corp · Expires 2005-06-29 · 21y expired

What this patent protects

提供了口内崩解的伐地考昔速溶片剂和制备这类剂型的方法。该组合物可用于治疗或预防环加氧酶－2介导的病症和障碍。

USPTO Abstract

提供了口内崩解的伐地考昔速溶片剂和制备这类剂型的方法。该组合物可用于治疗或预防环加氧酶－2介导的病症和障碍。

Drugs covered by this patent

Emend (APREPITANT) · Merck & Co.

Patent Metadata

Patent number: CN1633281A
Jurisdiction: CN
Classification: —
Expires: 2005-06-29
Drug substance claim: No
Drug product claim: No
Assignee: PharMetrix Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.